Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Abstract Text:

Lucia Nogová,Thomas Rudiger,Andreas Engert,

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) differs in histological and clinical presentation from classical Hodgkin lymphoma (cHL). The typical morphologic signs of NLPHL are atypical "lymphocytic and histiocytic" (L&H) cells, which are surrounded by a non-neoplastic nodular background of small lymphocytes of B-cell origin. The NLPHL cells are positive for CD45, CD19, CD20, CD22 and CD79a, but lack expression of CD15 and CD30, the typical markers for cHL. NLPHL patients are predominantly of male gender with a median age of 37 years. Patients often present in early stages (63%) and rarely have B-symptoms (9%). Treatment of NLPHL patients using standard Hodgkin lymphoma (HL) protocols leads to complete remission (CR) in more than 95% of patients. Survival and freedom from treatment failure (FFTF) are worse in advanced-stage patients than in early-stage patients. Thus, patients in advanced and in early stages with unfavorable risk factors are treated similarly to cHL patients. In contrast, patients with early-stage NLPHL without risk factors can be sufficiently treated with reduced intensity programs having less severe adverse effects. As a result, treatment of early NLPHL is less clearly defined, including radiotherapy in extended field (EF) or involved field (IF) technique, combined modality treatment, and, more recently, monoclonal antibody rituximab. Watch and wait strategy plays an important role in pediatric oncology to avoid adverse effects associated with therapy.

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Publishing Authors By Initials

L Nogová,T Rudiger,A Engert,

For similar therapeutics: remission induction research abstracts see: therapeutics: remission induction research

PUBMED ID PMID:

MEDLINE DATE:

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Journal Published:

PUBLICATION TYPE: Review

Journal: Hematology / the Education Program of the American

VOLUME:

Page Numbers: 266-72

Journal Abbreviation:

ISSN: 1520-4391

DAY: 12

MONTH: 02

YEAR: 2006

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Information

Number of References: 43

LANGUAGE: eng

NlmUniqueID: 100890099

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Keywords Mesh Terms:

KEYWORDS: Remission Induction

MESH TERMS: methods

Chemical & Substance for Abstract: Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.

AFFILIATION: German Hodgkin Study Group, Clinic I for Internal Medicine, University Hospital Cologne, Kerpenerstr. 62, 50924 Cologne, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hematology Am Soc Hematol Educ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma Related Publications

• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
• Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
• Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
• Control of visually guided behavior by distinct populations of spinal projection neurons.
• Current treatment strategies of the German Hodgkin Study Group (GHSG).
• Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
• Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
• Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons.
• Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
• Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study.
• Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
• Hodgkin's disease. Future treatment strategies: fact or fiction?
• Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells.
• Immunotherapy of Hodgkin's lymphoma.
• K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
• Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
• Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
• [Antibiotic therapy of endocarditis lenta.]
• [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]
• [Thoracic surgery emergencies in early childhood]